Therapeutic Research

Abstract

Background：We have reported on the administration of PARSABIV®（hereinafterreferred to as etelcalcetide）to patients with maintenance hemodialysis with SecondaryHyperparathyroidism.　　Cases：A total of 18 cases, 9 cases of novel administration and 9 cases of switchingfrom cinacalcet were examined. Etelcalcetide dosage（3 times a week for each case）：5mg；16 cases（ new and switching, eight cases of each）, 2.5 mg；2 cases（new andswitching, one case of each）.　　Results：In switching from the cinacalcet to the etelcalcetide, the average levels ofi‒PTH was 188.9 pg/mL before switching, and greatly increased to 200.2 pg/mL after1 month, and 123.2 pg/mL after 3 months. The pre‒dose of cinacalcet in the switchingexample was 25 mg：7 cases, 50 mg：2 cases. Adjusted serum calcium scarcely changed.In the case of new administration of etelcalcetide, the average levels of i‒PTH was 533.3 pg/mL before administration, and 513.1 pg/mL after 1 month, 148.6 pg/mL after 3 months, that is, the effect was also recognized after 3 months. Decrease in dosage, weight loss, side effects, and patient opinion of other drugs were considered. There was no case of discontinuation of administration within 3 months from the start of administration. Conclusion：It has been revealed the tolerance and safety after switching from the 25 mg of cinacalcet to the 5 mg of etelcalcetide. Etelcalcetide is promising for improving the prognosis of patients with secondary hyperparathyroidism.